RegeneRx

Shareholder letter - Tuesday February 17, 2015

Link to document.

RegeneRx Pipeline

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.

Latest News:

February 1, 2016
RegeneRx Meeting with Institutional Investors and Analysts At BIO CEO Conference


January 28, 2016
RegeneRx U.S. Joint Venture, ReGenTree, Launches Web Site


January 27, 2016
RegeneRx's TB4 Shown to Promote Regeneration and Repair of Damaged Central Nervous System Cells


December 23, 2015
RegeneRx Joint Venture Posts Results of Severe Dry Eye Trial On ClinicalTrials.gov


December 4, 2015
RegeneRx Receives Chinese Patent for Key TB4 Peptide Fragment


October 28, 2015
RegeneRx Analyst Report Update Issued by SeeThruEquity, LLC